Evidence map›Paper›PMID 31326978›Full record

ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2020

Associations of Hearing Loss and Menopausal Hormone Therapy With Change in Global Cognition and Incident Cognitive Impairment Among Postmenopausal Women.

Nicole M Armstrong, Mark A Espeland, Jiu-Chiuan Chen, Kamal Masaki, Jean Wactawski-Wende, Wenjun Li, Margery L S Gass, Marcia L Stefanick, JoAnn E Manson, Jennifer A Deal and 3 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 1 country.

Nicole M ArmstrongLaboratory of Behavioral Neuroscience, National Institute of Aging, Baltimore, Maryland.
Mark A EspelandDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Jiu-Chiuan ChenDepartment of Preventive Medicine and Neurology, Keck School of Medicine of University of Southern California, Los Angeles, California.
Kamal MasakiDepartment of Geriatric Medicine, John A. Burns School of Medicine, University of Hawai`i Manoa, Honolulu, Hawaii.
Jean Wactawski-WendeDepartment of Epidemiology and Environmental Health, School of Public Health and Health Professions, University of Buffalo, New York.
Wenjun LiDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts.
Margery L S GassDepartment of Obstetrics & Gynecology, University of Cincinnati, Cincinnati, Ohio.
Marcia L StefanickDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
JoAnn E MansonDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Jennifer A DealDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Stephen R RappDepartment of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Frank R LinDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Susan M ResnickLaboratory of Behavioral Neuroscience, National Institute of Aging, Baltimore, Maryland.
Johns Hopkins University · USNational Institute on Aging · USWake Forest University · USBrigham and Women's Hospital · USStanford University · USUniversity at Buffalo, State University of New York · USUniversity of Cincinnati · USUniversity of Hawaiʻi at Mānoa · USUniversity of Massachusetts Chan Medical School · USUniversity of Southern California · US

Funding

USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Hussein N Yassine · 2020 to 2026
$27.8M
Women's Health Initiative Suite of Studies - Extension StudyZIAAG000190 · NIA · NATIONAL INSTITUTE ON AGING · PI RESNICK, SUSAN · 2009 to 2024
$1.5M
Role and Mechanism of Hearing Impairment in Cognitive Decline and DementiaK01AG054693 · NIA · JOHNS HOPKINS UNIVERSITY · PI DEAL, JENNIFER ANNE · 2017 to 2022
$773k
NHLBI NIH HHS HHSN268201600001CNHLBI NIH HHS HHSN268201600002CNHLBI NIH HHS HHSN268201600003CNHLBI NIH HHS HHSN268201600004CNHLBI NIH HHS HHSN268201600018CNIA NIH HHS K01 AG054693NIA NIH HHS P30 AG066530
6 · The paper itself

Abstract

backgroundHearing loss (HL) and menopausal hormone therapy (conjugated equine estrogens [CEE] and/or medroxyprogesterone acetate [MPA]) are separately associated with cognitive decline and increased risk of incident cognitive impairment. Joint effects of HL and HT could be associated with additive or synergistic decline in global cognition and risk of incident cognitive impairment among postmenopausal women.

methodsUsing the Women's Health Initiative (WHI) Memory Study, 7,220 postmenopausal women with measures of HL, global cognition (Modified Mini-Mental State Examination score), and cognitive impairment (centrally adjudicated diagnoses of mild cognitive impairment and dementia) from 1996 to 2009. Multivariable linear mixed-effects models were used to analyze rate of change in global cognition. Accelerated failure time models were used to evaluate time to incident cognitive impairment, stratified by HT.

resultsWithin the CEE-Alone trial, observed adverse effects of CEE-Alone on change in global cognition did not differ by HL, and estimated joint effects of HL and CEE-Alone were not associated with incident cognitive impairment. Within the CEE+MPA trial, while HL did not independently accelerate time to cognitive impairment, the adverse effect of CEE+MPA on global cognition was heightened in older women with HL. Older women on CEE+MPA either with HL (time ratio [TR] = 0.82, 95% confidence interval [CI]: 0.71, 0.94) or with normal hearing (TR = 0.86, 95% CI: 0.76, 0.97) had faster time to cognitive impairment than those with normal hearing and placebo.

conclusionsHL may accentuate the adverse effect of CEE+MPA, not CEE-Alone, on global cognitive decline, not incident cognitive impairment, among postmenopausal women on HT.

Indexed as

CognitionAgedCognitive DysfunctionEstrogens, Conjugated (USP)FemaleHearing LossHormone Replacement TherapyHumansMedroxyprogesterone AcetatePostmenopauseEstrogens, Conjugated (USP)Medroxyprogesterone AcetateCognitive declineCognitive impairmentHearing lossHormone therapy

Identifiers

PMID31326978
PMCPMC7205420
OpenAlexW2963122362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.